NCT04768985View on ClinicalTrials.gov

Study to Assess the Bioequivalence of Acalabrutinib Tablet and Acalabrutinib Capsule

PHASE1CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

February 25, 2021

Primary Completion Date

May 10, 2021

Study Completion Date

May 10, 2021

Conditions
Bioequivalence
Interventions
DRUG

Treatment A: Acalabrutinib tablet

Participants will receive fixed single doses of acalabrutinib tablet in 2 treatment periods, under fasted conditions.

DRUG

Treatment B: Acalabrutinib capsule

Participants will receive fixed single doses of acalabrutinib capsule in 2 treatment periods, under fasted conditions.

Trial Locations (3)

21225

Research Site, Brooklyn

84107

Research Site, Salt Lake City

91206

Research Site, Glendale

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY